Menu
Not yet recruiting NCT06549387

Topo-Pachymetric Customized Accelerated Epi-On Vs Accelerated Epi-Off Corneal Cross Linking in Keratoconus Management

No phase Interventional Amount of Corneal Flattening (Kmax Flattening) Change in the Endothelial Cell Count

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Corneal cross linking.
Who it may be relevant to
Registry conditions: Amount of Corneal Flattening (Kmax Flattening), Change in the Endothelial Cell Count. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Topo-Pachymetric Customized Accelerated Epithelium-On Versus Standard Accelerated Epithelium-Off Corneal Collagen Cross Linking in the Management of Keratoconus

Overview

The objective of this study is to compare the clinical effectiveness and safety of Topo-Pachymetric Customized Accelerated Epithelium-On (aCFXL) to Standard Accelerated Epithelium-Off (aCXL) Corneal Collagen Cross-Linking in the management of keratoconus. The study aims to evaluate visual and structural outcomes, to provide valuable insights into optimizing treatment strategies.

Interventions

  • Procedure Corneal cross linking
    Applying UVA irradiation to the cornea after soaking with riboflavin

Primary outcome measures

  • Amount of corneal flattening [Time frame: 6 months]
  • Change in the endothelial cell count. [Time frame: 6 months]
Secondary outcome measures (1)
  • Best corrected visual acuity [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Age: 18 years or older
  • Corrected distance visual acuity (CDVA) of ≥ 0.3 Snellen.
  • Central corneal thickness (de-epithelialized) of ≥ 400 micron.
  • Corneal endothelial count of ≥ 2000.

Exclusion criteria

  • Previous eye surgery
  • The presence of lesions other than keratoconus, central or paracentral scaring
  • History of Cross linking
  • History of viral keratitis
  • Connective tissue diseases
  • Pregnancy or lactation during the study.
  • The presence of nystagmus

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Kasr Al Ainy — Cairo

Identifiers

NCT: NCT06549387 · _MD-402-2023_

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗